SLFN11 expression levels change dynamically during treatment: while 70% of circulating tumor cells expressed SLFN11 in treatment-naive patients, this proportion decreased to 25% in patients receiving platinum therapy. The gene discussed is SLFN11; the disease is neoplasm.